Previous 10 | Next 10 |
The first patient has been enrolled in United Therapeutics' (UTHR) phase 3 TETON study, which is expected to evaluate approx. 396 adult patients with idiopathic pulmonary fibrosis ((IPF)).This 52-week study will evaluate the impact of Tyvaso on a key prognostic indicator for IPF known as forc...
United Therapeutics Announces First Patient Enrolled In Phase 3 TETON Study Of Tyvaso In Patients With Idiopathic Pulmonary Fibrosis First pivotal study of Tyvaso® (treprostinil) Inhalation Solution outside pulmonary hypertension PR Newswire SILVER SPRING, Md....
United Therapeutics Corporation To Present At The Jefferies Virtual Healthcare Conference PR Newswire SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , May 25, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that M...
MannKind opts for dropping their DPI platform and moving in a new direction. Afrezza sales have hit a plateau of stagnant new prescriptions. Details of the United Therapeutics partnership aren't encouraging for MannKind. A truly questionable purchase of a company and the drug ...
Palm Beach, FL – May 12, 2021 – Autism spectrum disorder (ASD) represents a group of neurodevelopmental disorders or disabilities; it is a heritable and a polygenic disorder. Autism spectrum disorder is lifelong and typically emerges during early childhood. Children show ASD-r...
After a dull 2020, value stocks are back in action. Amid the economy’s reopening, many fundamentally sound stocks that lost significant value last year have started rebounding. Furthermore, we think inflationary pressure in the United States and concerns over the market’s overva...
Image source: The Motley Fool. United Therapeutics Corp (NASDAQ: UTHR) Q1 2021 Earnings Call May 5, 2021 , 9:00 a.m. ET Operator Continue reading For further details see: United Therapeutics Corp (UTHR) Q1 2021 Earnings Call Transcript
United Therapeutics Corporation (UTHR) Q1 2021 Earnings Conference Call May 05, 2021, 09:00 AM ET Company Participants Dewey Steadman - Head, IR Martine Rothblatt - Chairperson and CEO Michael Benkowitz - President and COO Leigh Peterson - SVP, Product Development James Edgemond - CFO and Tre...
United Therapeutics (UTHR): Q1 Non-GAAP EPS of $3.49 in-line; GAAP EPS of $0.61 misses by $2.34.Revenue of $379.1M (+6.4% Y/Y) beats by $10.15M.Press Release For further details see: United Therapeutics EPS in-line, beats on revenue
United Therapeutics Corporation Reports First Quarter 2021 Financial Results Tyvaso® (treprostinil) Inhalation Solution approved for pulmonary hypertension associated with interstitial lung disease (PH-ILD) Tyvaso DPI™ New Drug Application (NDA) submitted to U.S....
News, Short Squeeze, Breakout and More Instantly...
United Therapeutics Corporation Company Name:
UTHR Stock Symbol:
NASDAQ Market:
United Therapeutics Corporation Website:
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...
2024-07-11 06:30:06 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for UTHR on July 11, 2024 04:53AM ET. The previous analyst recommendation was Overweight. UTHR was trading at $329.25 at issue of the analyst recommendation. The overall analyst consensus : ...
Over 100,000 patients in the United States have IPF, with two approved therapies available that only slow the course of disease progression Top line data expected in the second half of 2025 United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announ...